1.34
前日終値:
$1.31
開ける:
$1.27
24時間の取引高:
32,790
Relative Volume:
0.23
時価総額:
$4.29M
収益:
$129.20K
当期純損益:
$-7.44M
株価収益率:
-0.1197
EPS:
-11.19
ネットキャッシュフロー:
$-8.62M
1週間 パフォーマンス:
-4.29%
1か月 パフォーマンス:
-13.55%
6か月 パフォーマンス:
-79.97%
1年 パフォーマンス:
-90.99%
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
名前
Sonnet Biotherapeutics Holdings Inc
セクター
電話
609-375-2227
住所
100 OVERLOOK CENTER, PRINCETON, NJ
SONN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
SONN
Sonnet Biotherapeutics Holdings Inc
|
1.34 | 4.29M | 129.20K | -7.44M | -8.62M | -11.19 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc (SONN) 最新ニュース
Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter
SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener
Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire
Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World
Sonnet BioTherapeutics secures new IL-18 patent - Investing.com
Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks
Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire
Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties - StockTitan
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq
Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan
XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire
Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - The Manila Times
Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq
Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire
Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan
Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - Defense World
Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com Australia
Sonnet BioTherapeutics advances novel ADC platform - Investing.com
SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India
Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com
Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire
Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail
Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - The Manila Times
Sonnet BioTherapeutics Announces Acceptance of Poster Presentation at 2025 AACR IO Conference - Nasdaq
Revolutionary Cancer Treatment Breakthrough: Sonnet's IL-12 Protein Research Heads to AACR 2025 - StockTitan
Sonnet BioTherapeutics appoints new chief business officer - MSN
Sonnet BioTherapeutics Issues Financial Results for Q4 2024, Reports Progress in Clinical Trials and Business Development - Defense World
Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments - TipRanks
Sonnet BioTherapeutics appoints new chief business officer By Investing.com - Investing.com Nigeria
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Sonnet BioTherapeutics reports wider Q1 net loss, CFO transition - MSN
Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer -February 13, 2025 at 08:40 am EST - Marketscreener.com
Sonnet Biotherapeutics Holdings Inc (SONN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):